Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes

Journal of Psychiatric Research

Volumn 47, Issue 9, 2013, Pages 1204-1214

  Ookubo, Masanori ^a,b   Kanai, Hirohiko ^a   Aoki, Harusuke ^b   Yamada, Naoto ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Minakuchi Hospital   (Japan)

Author keywords

Acetylated histone H3; Amygdala; Cingulate cortex; Depression; Histone deacetylases; Striatum

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLOZAPINE; DULOXETINE; ESCITALOPRAM; ETIRACETAM; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; LAMOTRIGINE; LITHIUM CHLORIDE; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84880136498     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.05.028     Document Type: Article

References (40)

1. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Current Opinion in Pharmacology 2008, 8(1):57-64.
2. Arban R., Maraia G., Brackenborough K., Winyard L., Wilson A., Gerrard P., et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behavioural Brain Research 2005, 158(1):123-132.
3. Baltan S., Bachleda A., Morrison R.S., Murphy S.P. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Translational Stroke Research 2011, 2(3):411-423.
4. Belzeaux R., Formisano-Treziny C., Loundou A., Boyer L., Gabert J., Samuelian J.C., et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. Journal of Psychiatric Research 2010, 44(16):1205-1213.
5. Bhaumik S.R., Smith E., Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nature Structural & Molecular Biology 2007, 14(11):1008-1016.
6. Brocco M., Dekeyne A., Veiga S., Girardon S., Millan M.J. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacology, Biochemistry and Behavior 2002, 71(4):667-680.
7. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. Journal of Molecular Neuroscience 2007, 31(1):47-58.
8. Can A., Blackwell R.A., Piantadosi S.C., Dao D.T., O'Donnell K.C., Gould T.D. Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes, Brain and Behavior 2011, 10(4):434-443.
9. Castagne V., Porsolt R.D., Moser P. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. European Journal of Pharmacology 2009, 616(1-3):128-133.
10. Colvis C.M., Pollock J.D., Goodman R.H., Impey S., Dunn J., Mandel G., et al. Epigenetic mechanisms and gene networks in the nervous system. The Journal of Neuroscience 2005, 25(45):10379-10389.
11. Consoli D., Leggio G.M., Mazzola C., Micale V., Drago F. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. European Journal of Pharmacology 2007, 573(1-3):139-147.
12. Dawe G.S., Nagarajah R., Albert R., Casey D.E., Gross K.W., Ratty A.K. Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse. Neuroscience 2010, 171(1):162-172.
13. Dencker D., Dias R., Pedersen M.L., Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy & Behavior 2008, 12(1):49-53.
14. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behavioural Brain Research 2010, 207(1):78-83.
15. Fuller R.W., Hemrick-Luecke S.K., Snoddy H.D. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. Journal of Pharmacology and Experimental Therapeutics 1994, 269(1):132-136.
16. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 2001, 20(24):6969-6978.
17. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389(6649):349-352.
18. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. The Journal of Clinical Psychiatry 2000, 61(Suppl. 6):4-6.
19. Hobara T., Uchida S., Otsuki K., Matsubara T., Funato H., Matsuo K., et al. Altered gene expression of histone deacetylases in mood disorder patients. Journal of Psychiatric Research 2010, 44(5):263-270.
20. Hsieh J., Gage F.H. Chromatin remodeling in neural development and plasticity. Current Opinion in Cell Biology 2005, 17(6):664-671.
21. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research 2011, 3(2):166-179.
22. Klenotich S.J., Seiglie M.P., McMurray M.S., Roitman J.D., Le Grange D., Dugad P., et al. Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice. Neuropsychopharmacology 2012, 37(7):1620-1631.
23. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705.
24. Kubera M., Roman A., Basta-Kaim A., Budziszewska B., Zajicova A., Holan V., et al. Effect of acute and repeated treatment with mirtazapine on the immunity of noradrenaline transporter knockout C57BL/6J mice. Pharmacology Biochemistry and Behavior 2006, 85(4):813-819.
25. Langen B., Dost R., Egerland U., Stange H., Hoefgen N. Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test. Psychopharmacology (Berl) 2012, 221(2):249-259.
26. Langley B., Gensert J.M., Beal M.F., Ratan R.R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Current Drug Targets CNS & Neurological Disorders 2005, 4(1):41-50.
27. MacDonald J.L., Roskams A.J. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Developmental Dynamics 2008, 237(8):2256-2267.
28. Marsoni S., Damia G., Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008, 3(3):164-171.
29. Mombereau C., Gur T.L., Onksen J., Blendy J.A. Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. The International Journal of Neuropsychopharmacology 2010, 13(3):321-334.
30. Ohno Y., Ishihara S., Terada R., Serikawa T., Sasa M. Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. Epilepsy Research 2010, 89(2-3):360-364.
31. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 2001, 276(39):36734-36741.
32. Renard C.E., Dailly E., Nic Dhonnchadha B.A., Hascoet M., Bourin M. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test?. Progress in Neuropsychopharmacology & Biological Psychiatry 2004, 28(8):1255-1259.
33. Renthal W., Maze I., Krishnan V., Covington H.E., Xiao G., Kumar A., et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56(3):517-529.
34. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biological Psychiatry 2007, 62(1):55-64.
35. Takahashi E., Niimi K., Itakura C. Levetiracetam-mediated emotional behavior in heterozygous rolling Nagoya Ca(V)2.1 channel mutant mice. Pharmacology Biochemistry and Behavior 2010, 96(3):294-300.
36. Taylor M.J., Freemantle N., Geddes J.R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry 2006, 63(11):1217-1223.
37. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nature Reviews Neuroscience 2007, 8(5):355-367.
38. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience 2006, 9(4):519-525.
39. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37):5541-5552.
40. Yu J., Liu Q., Wang Y.Q., Wang J., Li X.Y., Cao X.D., et al. Electroacupuncture combined with clomipramine enhances antidepressant effect in rodents. Neuroscience Letters 2007, 421(1):5-9.